VRNS VARONIS SYSTEMS INC Insider Trading

Director Gavin John J Jr bought 5,000 shares of VRNS at $22.54; stock now -58.5% from 52-week high; 3 other insiders bought within 14 days

Director Gavin John J Jr purchased 5,000 shares at $22.54, increasing his holdings to 273.7K shares in a company currently priced at $26.26, which is -58.5% from its 52-week high of $63.31. The company generated $161.6M in latest-quarter revenue with +13.2% annual growth, but posted a net loss of $-29.9M and remains unprofitable on a full-year basis. Notably, this purchase is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated confidence amid significant stock price pressure and operating losses. The timing occurs as VRNS stock has declined -25.5% over 30 days and -26.1% over 90 days, yet insiders are accumulating; investors should monitor whether this buying cluster reflects contrarian positioning by informed parties or if management views valuations as attractive despite current profitability challenges.

CEO Faitelson buys 26,725 shares at $22.41; 3 other insiders bought within 14 days as stock trades -58.5% from 52-week high.

Faitelson Yakov, CEO/President/Chairman, purchased 26,725 shares at $22.41 on 2026-02-09, increasing his holdings to 285,312 shares (+10.3% from prior position). The buy occurs with the stock trading at $26.26, down 58.5% from its 52-week high of $63.31 and down 25.5% over the past 30 days. Notably, a cluster of 3 other insiders also bought within the past 14 days, suggesting synchronized acquisition activity. The company reported revenue of $161,577,000.00 in the latest quarter with annual revenue growth of +13.2%, but was unprofitable with net income of -$29,942,000.00 and a full-year loss. The CEO's prior trading history at VRNS (2 prior sells in May 2024) showed 0 of 2 well-timed at the 90-day mark, with the stock rising 20.7% and 13.0% after those sales, respectively. This buy at a depressed price level coinciding with a broader insider purchase pattern merits observation of whether subsequent price action confirms or contradicts the multi-insider accumulation signal.

EVP Engineering David Bass buys 2,980 shares of VRNS at $23.47; stock down 58.5% from 52-week high; 3 other insiders also bought in past 14 days.

David Bass, EVP Engineering & CTO, purchased 2,980 shares at $23.47 on 2026-02-09 while VRNS trades at $26.26, well below its 52-week high of $63.31 and down 25.5% in the past 30 days. This transaction occurs within a broader cluster pattern: 3 other insiders also bought within the past 14 days. Bass's own cross-ticker track record shows strong sell-timing (75.00% well-timed rate on 8 prior sales averaging +3.1% 30-day returns), but his same-ticker history at VRNS tells a different story—5 prior sales were all well-timed at the 90-day mark, uniformly followed by declines. The company is unprofitable (net income $-29.9M in the latest quarter) despite revenue growth of 13.2% annually, and carries a $3.1B market cap. The convergence of multiple insider purchases during a sharp recent decline, combined with Bass's mixed track record at this specific ticker, warrants examination of whether the recent price action has attracted opportunistic buying or whether foundational concerns persist.

Director Kess Avrohom J. purchases 17,800 shares of VRNS at $22.29; holdings rise to 49,403 shares as stock trades -58.5% from 52-week high

Kess Avrohom J. purchased 17,800 shares at $22.29 on 2026-02-06, expanding his position by 56.3% to 49,403 shares total. The transaction occurs while VRNS stock is trading -58.5% from its 52-week high of $63.31 and down 25.5% over the past 30 days. At VRNS specifically, Kess's prior two open-market purchases (2024-02-12 and 2023-08-04) showed mixed results: one declined 14.0% at the 90-day mark, while the other gained 12.2%. Notably, a cluster of 3 other insiders also bought VRNS within the past 14 days, suggesting coordinated interest in the name. The company remains unprofitable (net income $-29.9M) despite 13.2% annual revenue growth, creating a contrarian timing signal in a significantly depressed stock price.

CFO/COO Melamed Guy sold 10,400 shares of VRNS at $59.53 on 2025-08-22; stock now at $57.39, unprofitable company with recent pattern of well-timed sells.

Melamed Guy, CFO and COO, sold 10,400 shares at $59.53, reducing his VRNS holdings to 417,497 shares. The sale occurred near the 52-week high of $59.98 and the stock has since declined -4.3%, trading at $57.39. Across his prior five trades at VRNS, Melamed has demonstrated strong timing discipline: 3 of 3 prior measurable sales yielded negative 90-day returns (-12.0%, -13.2%, -20.2%), and his cross-ticker track record shows a 100.00% well-timed rate on 7 prior sells. The sale is noteworthy given Varonis' unprofitable status (full-year net income negative, latest quarter showing $-35.8M net income) despite +10.4% annual revenue growth, suggesting the CFO may be responding to margin pressures or profitability concerns.

CFO Guy Melamed sold 42,705 shares at $57.72; all 4 measurable prior VRNS sales were negative 90-day performers

Guy Melamed (CFO and COO) sold 42,705 shares at $57.72 on 2025-08-13, reducing holdings by 9.1% from 470.6K to 427.9K shares. His prior four sales at VRNS between February and November 2024 were all well-timed at the 90-day mark: two sales on 2024-11-13 returned -12.0% and -13.2% respectively, one on 2024-02-08 returned -20.2%, and another on 2024-02-08 returned -0.3% and -8.6% at 90 days. This pattern of consistent negative returns after his VRNS sales—all 4 of 4 prior sells well-timed—suggests an identifiable ability to exit before subsequent declines at this ticker specifically. The company remains unprofitable with net income of $-35.8M against $152.2M quarterly revenue, despite 10.4% annual revenue growth. The current stock price is $58.41, only 2.6% below the 52-week high, and has rallied +16.1% in the past 30 days and +26.1% in 90 days—making this sale occur near elevated valuations.

CFO Melamed Guy sold 51,889 shares of VRNS at $55.10 for $2,859,083.90; 5 prior same-ticker sells all well-timed at 90d mark.

Melamed Guy sold 51,889 shares (51.9K shares) at $55.10 on 2025-08-01, reducing his VRNS holdings by 9.9% from 522,491 to 470,602 shares. This sale is particularly notable given his prior trade history at this ticker: he has executed 5 previous sales at VRNS, and all 5 were well-timed (showing negative 90-day returns, with a perfect timing pattern of 5 of 5 at the 90-day mark). His cross-ticker track record also shows a 100.00% 90-day well-timed rate across 5 prior sells, with an average 90-day return of -13.0%, indicating consistent execution before subsequent declines. The company remains unprofitable (net income $-35,824,000.00 for the latest quarter) despite 10.4% annual revenue growth, which provides context for elevated insider selling activity by a senior financial executive.

CFO/COO Melamed Guy sold 91,345 shares ($4.9M) at $53.70 avg; stock now $51.08, down 14.8% from 52-week high.

Melamed Guy executed 2 separate sales totaling 91,345 shares for $4,905,444.08 at a blended average price of $53.70, reducing his holdings by 15.3%. The shares have since declined to $51.08, positioning this as a well-timed exit within the context of his prior trading activity at VRNS: 3 of 3 earlier sales at this ticker showed negative 90-day returns, establishing a consistent pattern of selling before declines. His cross-ticker track record shows a 100.00% well-timed rate across 3 prior sells with an average 90-day return of -7.8%. The broader context shows VRNS trading 14.8% below its 52-week high and the company running unprofitable ($-18,333,000.00 net income in the latest quarter), suggesting the CFO's recent sale aligns with deteriorating financial performance. This level of executive liquidation—reducing a significant portion of C-suite holdings while the stock faces headwinds—merits investor attention.

Vice Chairman O'Boyle sold 50,000 VRNS shares at $59.76 for $3.0M; now holds 444.1K shares. Stock at $58.97.

O'Boyle sold 50,000 shares (444.1K remaining) near the 52-week high of $59.98, with the stock up 24.1% over 90 days and +9.4% over 30 days. At VRNS specifically, his prior 3 measurable 90-day sell outcomes all resulted in positive returns (+7.3%, +7.9%, +7.5%), meaning the stock rose after he sold—a 0% well-timed rate at this ticker. Across his broader open-market history, his 5 prior sells averaged a 7.6% 90-day return with a 0.00% well-timed rate, indicating a consistent pattern of selling before rallies rather than declines. Against this backdrop, the company is unprofitable (net income -$23.9M in the latest quarter) despite 5.4% annual revenue growth, introducing execution risk despite the recent stock momentum.

Vice Chairman O'Boyle sold 75,000 VRNS shares (75.0K) for $3,828,054.70 at blended $51.04 on 2024-08-06

O'Boyle executed 2 separate sales totaling 75,000 shares for $3,828,054.70, reducing his holdings from 569,114 to 494,114 shares (-13.2%). The sale occurred at $51.04 blended average, below the current price of $53.75. At VRNS specifically, O'Boyle's 3 prior open-market sales (all in December 2023) were followed by positive 90-day returns averaging +7.6%, meaning the stock rose after those sales — a pattern of poorly-timed exits that mirrors his cross-ticker record of 0.00% well-timed sell rate. The company remains unprofitable (full-year net income negative, recent quarterly net income $-23,948,000.00) despite 5.4% annual revenue growth, creating a backdrop of execution challenges offsetting top-line momentum. This latest sale extends a consistent pattern of discretionary stock dispositions that have not preceded price declines.